Source: High Yields
  • Sugarbud Craft Growers Corp. (SUGR) has amended the terms of its public offering of convertible debenture units
  • Sugarbud has reduced the conversion price of the convertible debentures from $1.39 to $1.29 per common share
  • Each debenture unit will consist of one 12.0 per cent secured convertible debenture and 775 common share purchase warrants
  • The company has also increased the size of the offering to up to $3,000,000 in gross proceeds
  • Sugarbud is a craft cannabis company focused on the cultivation and production of cannabis products
  • Sugarbud Craft Growers Corp. (SUGR) opened trading at C$1.29 per share

Sugarbud Craft Growers Corp. (SUGR) has amended the terms of its recently announced public offering of convertible debenture units.

Sugarbud has reduced the conversion price of the convertible debentures from $1.39 to $1.29 per common share and lowered the exercise price of the share purchase warrants from $1.39 to $1.29 per warrant. 

Each debenture unit will consist of one 12.0 per cent secured convertible debenture and 775 common share purchase warrants.

The company has also increased the size of the offering to up to $3,000,000 in gross proceeds.

Each warrant will entitle the holder to purchase one common share for a period of 5 years following the closing of the offering.

Debenture holders may elect to exchange their debentures for 15.0 per cent non-convertible secured notes.

The debentures will mature 5 years from the closing of the offering.

Sugarbud is a craft cannabis company focused on the cultivation and production of cannabis products.

Sugarbud Craft Growers Corp. (SUGR) opened trading at C$1.29 per share.

More From The Market Online
Cannabis Report image of farmed cannabis plants

The Market Online’s Weekly Cannabis Report – July 26, 2024

Tilray Oral Solution THC10:CBD10 cannabis extract, aka Tilray Solução Oral THC10:CBD10, has been approved for medical use in Portugal.
medical branch logo

Tilray approved for third medical cannabis product in Portugal

Tilray Medical, a subsidiary of Tilray Brands (TSX:TLRY) has been approved for a new medical cannabis extract in Portugal.